PL2803349T3 - Sposób wytwarzania wzbogaconej kompozycji IgG z osocza - Google Patents

Sposób wytwarzania wzbogaconej kompozycji IgG z osocza

Info

Publication number
PL2803349T3
PL2803349T3 PL14176511.5T PL14176511T PL2803349T3 PL 2803349 T3 PL2803349 T3 PL 2803349T3 PL 14176511 T PL14176511 T PL 14176511T PL 2803349 T3 PL2803349 T3 PL 2803349T3
Authority
PL
Poland
Prior art keywords
plasma
preparing
igg composition
enriched igg
enriched
Prior art date
Application number
PL14176511.5T
Other languages
English (en)
Polish (pl)
Inventor
Leopold Bruckschwaiger
Sonja Svatos
Julia NÜRNBERGER
Wolfgang Teschner
Harald Arno Butterweck
Hans-Peter Schwarz
Thomas Gundinger
Bernhard Koelbl
Reinhard Grausenburger
Azra Pljevljakovic
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2803349(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL2803349T3 publication Critical patent/PL2803349T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
PL14176511.5T 2010-05-26 2010-05-27 Sposób wytwarzania wzbogaconej kompozycji IgG z osocza PL2803349T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2010202125A AU2010202125B1 (en) 2010-05-26 2010-05-26 A method to produce an immunoglobulin preparation with improved yield

Publications (1)

Publication Number Publication Date
PL2803349T3 true PL2803349T3 (pl) 2024-02-26

Family

ID=42727304

Family Applications (4)

Application Number Title Priority Date Filing Date
PL14176511.5T PL2803349T3 (pl) 2010-05-26 2010-05-27 Sposób wytwarzania wzbogaconej kompozycji IgG z osocza
PL12190138T PL2554160T3 (pl) 2010-05-26 2010-05-27 Sposób wytwarzania z osocza kompozycji wzbogaconej w IgG
PL10727539T PL2445482T3 (pl) 2010-05-26 2010-05-27 Sposób wytwarzania z osocza kompozycji wzbogaconej IgG
PL11729200T PL2575762T3 (pl) 2010-05-26 2011-05-26 Usuwanie proteazy serynowej przez traktowanie subtelnie rozdrobnionym dwutlenkiem krzemu

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL12190138T PL2554160T3 (pl) 2010-05-26 2010-05-27 Sposób wytwarzania z osocza kompozycji wzbogaconej w IgG
PL10727539T PL2445482T3 (pl) 2010-05-26 2010-05-27 Sposób wytwarzania z osocza kompozycji wzbogaconej IgG
PL11729200T PL2575762T3 (pl) 2010-05-26 2011-05-26 Usuwanie proteazy serynowej przez traktowanie subtelnie rozdrobnionym dwutlenkiem krzemu

Country Status (25)

Country Link
US (6) US8993734B2 (enExample)
EP (6) EP2445482B1 (enExample)
JP (6) JP5876474B2 (enExample)
KR (3) KR101593265B1 (enExample)
CN (5) CN104958761B (enExample)
AR (4) AR076800A1 (enExample)
AU (8) AU2010202125B1 (enExample)
BR (2) BR112012029893B1 (enExample)
CA (2) CA2800155A1 (enExample)
CL (3) CL2012003291A1 (enExample)
CO (2) CO6660438A2 (enExample)
DK (3) DK2445482T3 (enExample)
EA (4) EA034602B1 (enExample)
ES (4) ES2959234T3 (enExample)
HK (1) HK1213790A1 (enExample)
HR (3) HRP20141109T1 (enExample)
HU (1) HUE064400T2 (enExample)
IL (2) IL223149A (enExample)
MX (4) MX349815B (enExample)
MY (3) MY160551A (enExample)
PL (4) PL2803349T3 (enExample)
PT (3) PT2445482E (enExample)
SG (3) SG10201505161SA (enExample)
TW (3) TWI531577B (enExample)
WO (1) WO2011149472A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CN102655853B (zh) * 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2011280907B2 (en) * 2010-07-23 2016-02-04 Takeda Pharmaceutical Company Limited Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma
HUE029232T2 (en) * 2011-04-08 2017-02-28 Univ Costa Rica A method for preparing injectable formulations of protein derived from blood, and materials obtained using said method
HRP20181118T1 (hr) 2011-12-13 2018-09-21 Baxalta GmbH Mjerenje autoprotutijela u uvjetima niske vodljivosti
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
RU2487725C1 (ru) * 2012-03-15 2013-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) Способ получения концентрированного иммуноглобулинового препарата для подкожного введения
CN103197053B (zh) * 2013-03-15 2015-02-18 上海市血液中心 一种抗IgA抗体检测试剂盒
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104086646B (zh) * 2014-07-03 2018-10-09 成都蓉生药业有限责任公司 血液制品中fv沉淀的制备方法
CN104072601A (zh) * 2014-07-03 2014-10-01 成都蓉生药业有限责任公司 血液制品中fii沉淀的制备方法
CN104086642A (zh) * 2014-07-03 2014-10-08 成都蓉生药业有限责任公司 血液制品中fi+iii上清的制备方法
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
US20170313767A1 (en) 2014-10-21 2017-11-02 The General Hospital Corporation Methods of diagnosis and treatment of tuberculosis and infection
CN204424090U (zh) 2014-11-28 2015-06-24 比亚迪股份有限公司 薄膜电容器
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
WO2016161423A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Process of cloning and further purification to make a recombinant intravenous immunoglobulin
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
WO2017058879A1 (en) * 2015-09-29 2017-04-06 Kieu Hoang A method of manufacturing intravenous immunoglobulin from fraction iii
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN106800583A (zh) * 2015-11-26 2017-06-06 上海洲跃生物科技有限公司 一种速溶无析出的冻干人纤维蛋白原制备工艺
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
EP3512496B1 (en) 2016-09-16 2025-07-30 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
CN109982716B (zh) * 2016-09-16 2024-05-10 白血球保健股份有限公司 在加工过程中稳定生物制药药物产品的新方法
EP3512939A1 (en) 2016-09-16 2019-07-24 Leukocare AG A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3060169A1 (en) * 2017-04-21 2018-10-25 Csl Behring Ag Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019121846A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
JP7465215B2 (ja) * 2018-04-12 2024-04-10 アムジェン インコーポレイテッド 安定なタンパク質組成物を製造する方法
CN108733099B (zh) * 2018-05-31 2020-08-11 上海药明生物技术有限公司 低pH孵育和中和的自动调节系统及方法
WO2021072137A1 (en) * 2019-10-11 2021-04-15 Baxalta Incorporated Heparin-insensitive assay for factor xla
CN114667151B (zh) * 2019-11-04 2025-05-23 万能溶剂有限公司 用于肌肉再生的血浆级分
WO2021099529A1 (en) * 2019-11-20 2021-05-27 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
JP7717715B2 (ja) * 2020-03-31 2025-08-04 武田薬品工業株式会社 Ｃ－１インヒビター欠乏血漿から免疫グロブリン製剤を生産する方法
KR20230024885A (ko) * 2020-04-10 2023-02-21 플라즈마 테크놀로지스, 엘엘씨 간소화된 고효율 단백질 단리를 위한 조성물 및 방법 (compositions and methods for simplified high efficiency isolation of proteins)
CN111961130B (zh) * 2020-08-31 2021-09-10 华兰生物工程重庆有限公司 一种从血浆中提取并分离IgM和IgG的方法
US20220106357A1 (en) * 2020-10-01 2022-04-07 Takeda Pharmaceutical Company Limited Plasma fractionation utilizing spray-dried human plasma
AU2021414086A1 (en) * 2020-12-28 2023-08-03 Plasma Technologies, Llc Systems and Methods for Process Scale Isolation of Immunoglobulin G
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法
MX2024001187A (es) 2021-07-29 2024-02-27 Csl Behring Ag Metodo para purificar inmunoglobulina g y usos de la misma.
CA3236213A1 (en) 2021-10-27 2023-05-04 Eugene ZURLO Compositions and methods for isolating proteins
KR102779378B1 (ko) * 2022-01-05 2025-03-12 한양대학교 에리카산학협력단 1-알릴이소크로만 유도체와 이의 제조방법
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법
MX2024010855A (es) 2022-03-07 2024-09-11 Takeda Pharmaceuticals Co Produccion cromatografica de afinidad de productos clinicos de inmunoglobulina g (igg) humana.
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
WO2023215722A1 (en) 2022-05-02 2023-11-09 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration
AR129690A1 (es) 2022-06-22 2024-09-18 Ageronix SA a1-ANTITRIPSINA PARA SU USO EN EL TRATAMIENTO DE ENFERMEDADES O TRASTORNOS DEL SISTEMA NERVIOSO COMO LA POLINEUROPATÍA DESMIELINIZANTE INFLAMATORIA CRÓNICA Y UN KIT
KR20250161658A (ko) 2023-03-29 2025-11-17 체에스엘 베링 아게 부작용과 관련된 면역글로불린을 식별하는 방법
WO2025008781A1 (en) 2023-07-04 2025-01-09 Csl Behring Ag Method of purification
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
WO2025085544A1 (en) * 2023-10-17 2025-04-24 Plasma Technologies, Llc Integrated process for isolation of plasma proteins
PL448469A1 (pl) * 2024-04-30 2025-11-03 Deveris Polska Spółka Z Ograniczoną Odpowiedzialnością Przedmiotem wynalazku jest sposób wzbogacania preparatów plazmy krwi drobiowej w immunoglobulinę G (IgG)
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (de) * 1977-01-26 1986-01-02 Armour Pharma GmbH & Co KG, 3440 Eschwege Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
US4296027A (en) 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3247150A1 (de) 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
DE3523615A1 (de) 1985-07-02 1987-01-15 Cytomed Medizintechnik Medizinisches geraet, insbesondere kanuele, katheter oder implantat
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) * 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
ATE122054T1 (de) * 1990-03-22 1995-05-15 Biotest Pharma Gmbh Verfahren zur herstellung eines intravenös verträglichen immunglobulin-g-präparates.
US5130451A (en) * 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) * 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AUPN858596A0 (en) * 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5783640A (en) * 1997-03-04 1998-07-21 The Goodyear Tire & Rubber Company Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
KR100632312B1 (ko) 1997-10-23 2007-05-14 미쯔비시 웰 파마 가부시키가이샤 실온저장가능한정맥내주사용면역글로불린제제
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (de) 1998-02-25 2000-10-25 Immuno Ag Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
ES2240180T3 (es) 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
DE10008519C1 (de) 2000-02-21 2001-07-12 Dica Technologies Ag Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet
DE10008619A1 (de) * 2000-02-24 2001-09-06 Immuno Vet As Lynge Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
WO2002030983A2 (de) 2000-10-13 2002-04-18 Octapharma Ag Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP1709077A1 (en) 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin
EP1718675B2 (en) 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
AU2006299293B2 (en) 2005-09-19 2011-08-18 Csl Behring Gmbh Factor H for the treatment of chronic nephropathies and production thereof
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
CN101374855A (zh) 2006-01-25 2009-02-25 奥克塔法马股份有限公司 促创伤愈合因子的纯化与应用
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1852443A1 (en) * 2006-05-05 2007-11-07 Leukocare AG Biocompatible three dimensional matrix for the immobilization of biological substances
DE102007001521A1 (de) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes
EP2129686B1 (en) * 2007-03-20 2016-07-13 CSL Behring GmbH Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
DE202007004346U1 (de) 2007-03-21 2007-10-31 Rehau Ag + Co Rohranordnung
JP2010524971A (ja) * 2007-04-20 2010-07-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン
JP2010529155A (ja) 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
EP2522752B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
CA2696417A1 (en) * 2007-10-02 2009-04-09 Csl Limited Therapeutic antibody purification method and method of use
AR069989A1 (es) 2007-12-28 2010-03-03 Baxter Int Formulaciones de vwf recombinantes
CN101249265B (zh) * 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 静脉注射用人乙肝免疫球蛋白及其制备方法
DK2291654T3 (en) 2008-05-28 2018-06-14 Prothera Biologics Inc PREPARATION AND COMPOSITION OF BLOOD INTER-ALPHA INHIBITOR PROTEINS
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
CN201169579Y (zh) * 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 一种人血白蛋白分离用乙醇雾化扩散装置
KR101772674B1 (ko) 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 ｖｗｆ 제제
ES2632394T3 (es) 2008-11-12 2017-09-12 Baxalta GmbH Purificación de butirilcolinesterasa usando adsorción a membrana
SG176256A1 (en) 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AT514675B1 (de) 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
SG10201809632XA (en) 2010-07-08 2018-12-28 Baxalta Inc METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
AU2011280907B2 (en) * 2010-07-23 2016-02-04 Takeda Pharmaceutical Company Limited Manufacture of inter -alpha - inhibitor proteins (IaIp) from plasma

Also Published As

Publication number Publication date
CN102970975A (zh) 2013-03-13
AU2018201371A1 (en) 2018-03-22
EP2803349B1 (en) 2023-09-27
JP2016155798A (ja) 2016-09-01
EA201291367A1 (ru) 2013-09-30
PT2554160E (pt) 2015-06-11
JP2013528183A (ja) 2013-07-08
AR121861A2 (es) 2022-07-20
US8940877B2 (en) 2015-01-27
JP2016053016A (ja) 2016-04-14
CA2800272A1 (en) 2011-12-01
EP2796128A1 (en) 2014-10-29
EA201291355A1 (ru) 2013-04-30
MX364252B (es) 2019-04-17
CN102970975B (zh) 2015-05-06
CO6660438A2 (es) 2013-04-30
CL2012003290A1 (es) 2013-10-18
AU2018201371B2 (en) 2019-10-31
MY173299A (en) 2020-01-14
EA034530B1 (ru) 2020-02-18
KR20130109016A (ko) 2013-10-07
PL2575762T3 (pl) 2015-01-30
PL2554160T3 (pl) 2015-07-31
HRP20141109T1 (hr) 2014-12-19
JP2018080207A (ja) 2018-05-24
HRP20150484T1 (hr) 2015-08-14
HK1203838A1 (en) 2015-11-06
AU2021286395A1 (en) 2022-01-20
MX2012013682A (es) 2013-01-28
EP2445482A1 (en) 2012-05-02
EA034602B1 (ru) 2020-02-25
BR112012029893A2 (pt) 2019-05-28
KR20130080450A (ko) 2013-07-12
US20210403504A1 (en) 2021-12-30
HK1213790A1 (zh) 2016-07-15
CN104958761A (zh) 2015-10-07
AR076800A1 (es) 2011-07-06
AU2024204779A1 (en) 2024-08-01
CL2012003291A1 (es) 2013-10-04
ES2505465T3 (es) 2014-10-10
US20130101579A1 (en) 2013-04-25
PT2575762E (pt) 2014-07-28
MY161617A (en) 2017-04-28
CN104840946A (zh) 2015-08-19
HUE064400T2 (hu) 2024-03-28
BR112012029897A2 (pt) 2016-08-16
AR082093A1 (es) 2012-11-14
MX337028B (es) 2016-02-09
CL2014003430A1 (es) 2015-05-04
AU2021286395B2 (en) 2024-04-11
SG10201505161SA (en) 2015-08-28
TWI543989B (zh) 2016-08-01
HK1215931A1 (zh) 2016-09-30
CN104958761B (zh) 2021-01-01
MX2019004482A (es) 2019-08-30
TW201141879A (en) 2011-12-01
JP5876474B2 (ja) 2016-03-02
KR101716534B1 (ko) 2017-03-14
CA2800155A1 (en) 2011-12-01
KR20160014119A (ko) 2016-02-05
CN103068365B (zh) 2015-07-08
SG185724A1 (en) 2013-01-30
EP2445482B1 (en) 2014-08-27
US11136350B2 (en) 2021-10-05
EP2803349C0 (en) 2023-09-27
AU2011258111A1 (en) 2012-12-13
BR112012029893B1 (pt) 2022-09-06
PL2445482T3 (pl) 2015-01-30
ES2959234T3 (es) 2024-02-22
JP5866345B2 (ja) 2016-02-17
EA025826B1 (ru) 2017-02-28
JP2013527201A (ja) 2013-06-27
EA201500848A1 (ru) 2016-06-30
US8993734B2 (en) 2015-03-31
AU2010224461A1 (en) 2010-10-21
EP2554160B1 (en) 2015-02-25
KR101593265B1 (ko) 2016-02-11
TWI504607B (zh) 2015-10-21
PT2445482E (pt) 2014-11-03
EP2575762B1 (en) 2014-07-09
IL223149A (en) 2017-02-28
US20150133644A1 (en) 2015-05-14
AU2010224461B2 (en) 2011-08-04
AU2010202125B1 (en) 2010-09-02
HK1181682A1 (en) 2013-11-15
ES2536093T3 (es) 2015-05-20
HK1170168A1 (en) 2013-02-22
DK2575762T3 (da) 2014-10-13
DK2445482T3 (da) 2014-09-22
TWI531577B (zh) 2016-05-01
CN109180776B (zh) 2022-12-13
EP2803349A1 (en) 2014-11-19
CO6660439A2 (es) 2013-04-30
EA023446B1 (ru) 2016-06-30
HRP20140944T1 (hr) 2014-12-05
TW201202263A (en) 2012-01-16
AU2016202973A1 (en) 2016-05-26
US20110293638A1 (en) 2011-12-01
HK1183449A1 (en) 2013-12-27
DK2554160T3 (da) 2015-04-27
EP4039249A1 (en) 2022-08-10
ES2525492T3 (es) 2014-12-23
MX2012013689A (es) 2013-01-28
MY160551A (en) 2017-03-15
KR101647617B1 (ko) 2016-08-10
US20240117009A1 (en) 2024-04-11
AU2020200373A1 (en) 2020-02-13
EA201691558A1 (ru) 2017-05-31
AU2020200373B2 (en) 2022-01-13
IL223150A0 (en) 2013-02-03
CN103068365A (zh) 2013-04-24
EP2554160A1 (en) 2013-02-06
EP2575762A2 (en) 2013-04-10
CN109180776A (zh) 2019-01-11
MX349815B (es) 2017-08-09
JP6592120B2 (ja) 2019-10-16
TW201542584A (zh) 2015-11-16
JP2017014297A (ja) 2017-01-19
US20180118782A1 (en) 2018-05-03
SG185725A1 (en) 2012-12-28
JP6363676B2 (ja) 2018-07-25
AR114228A2 (es) 2020-08-05
WO2011149472A1 (en) 2011-12-01
AU2011258111B2 (en) 2016-02-11
AU2016202973B2 (en) 2017-12-07
IL223149A0 (en) 2013-02-03

Similar Documents

Publication Publication Date Title
IL223150A0 (en) Method for preparing an enriched igg composition from plasma
EG27059A (en) Method for separating independent simultaneous sources
ZA201208540B (en) Process for preparing an immunoglobulin composition
EP2649088A4 (en) COMPOSITIONS FOR SEPARATION METHODS
ZA201305972B (en) Method for the preparation of biphephos
PL2539080T3 (pl) Sposób powlekania komponentów
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
GB201011442D0 (en) Apparatus & method
IL224694B (en) A method for producing an enriched library
IL222763A0 (en) Isotope preparation method
IL260947B (en) Methods for preparing an immunoglobulin preparation
GB201012037D0 (en) Apparatus & method
SG11201400909WA (en) Composition and method for producing same
EP2610338A4 (en) PROCESS FOR PRODUCTION OF SUBSTANCE
EP2653482A4 (en) PROCESS FOR PRODUCING PSEUDOPOLYROTAXANE
EP2551261A4 (en) PROCESS FOR PRODUCING OXIME
EP2599787A4 (en) PROCESS FOR PEPTIDE MANUFACTURE
ZA201403281B (en) Methods and compositions for neuroprotection
PL2380747T3 (pl) Sposób zapewniania paneli
HUP1100236A2 (en) Method for producing form pieces
GB201012231D0 (en) Apparatus & Method
PT2573065T (pt) Processo de produção de bioquerosene para aviação
GB201121008D0 (en) Apparatus & method
EP2599786A4 (en) PROCESS FOR PEPTIDE MANUFACTURE
GB201016079D0 (en) Apparatus & method